{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 6795, "items": [{"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T03:06:23Z", "timestamp": 1574219183134}, "reference-count": 46, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3318, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["BJU Int"], "published-print": {"date-parts": [[2006, 8]]}, "DOI": "10.1111/j.1464-410x.2006.06224.x", "type": "journal-article", "created": {"date-parts": [[2006, 7, 7]], "date-time": "2006-07-07T01:41:38Z", "timestamp": 1152236498000}, "page": "445-451", "source": "Crossref", "is-referenced-by-count": 33, "title": ["Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score"], "prefix": "10.1111", "volume": "98", "author": [{"given": "JOHN S.", "family": "LAM", "sequence": "first", "affiliation": []}, {"given": "DAVID B.", "family": "SELIGSON", "sequence": "additional", "affiliation": []}, {"given": "HONG", "family": "YU", "sequence": "additional", "affiliation": []}, {"given": "AI", "family": "LI", "sequence": "additional", "affiliation": []}, {"given": "MERVI", "family": "EEVA", "sequence": "additional", "affiliation": []}, {"given": "ALLAN J.", "family": "PANTUCK", "sequence": "additional", "affiliation": []}, {"given": "GANG", "family": "ZENG", "sequence": "additional", "affiliation": []}, {"given": "STEVE", "family": "HORVATH", "sequence": "additional", "affiliation": []}, {"given": "ARIE S.", "family": "BELLDEGRUN", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "b1_82", "author": "Parkin DM", "volume": "55", "first-page": "74", "year": "2005", "journal-title": "CA Cancer J Clin", "DOI": "10.3322/canjclin.55.2.74", "doi-asserted-by": "crossref"}, {"key": "b2_83", "DOI": "10.1002/cncr.20480", "doi-asserted-by": "publisher"}, {"key": "b3_84", "author": "Tso CL", "volume": "6", "first-page": "220", "year": "2000", "journal-title": "Cancer J"}, {"key": "b4_85", "DOI": "10.1097/00005392-200010000-00085", "doi-asserted-by": "publisher"}, {"key": "b5_86", "DOI": "10.1002/pros.10226", "doi-asserted-by": "publisher"}, {"key": "b6_87", "DOI": "10.1146/annurev.biochem.73.012803.092453", "doi-asserted-by": "publisher"}, {"key": "b7_88", "DOI": "10.1093/emboj/16.11.3341", "doi-asserted-by": "publisher"}, {"key": "b8_89", "DOI": "10.1074/jbc.275.6.4460", "doi-asserted-by": "publisher"}, {"key": "b9_90", "author": "Harrington JJ", "volume": "13", "first-page": "1235", "year": "1994", "journal-title": "EMBO J", "DOI": "10.1002/j.1460-2075.1994.tb06373.x", "doi-asserted-by": "crossref"}, {"key": "b10_91", "DOI": "10.1038/35086609", "doi-asserted-by": "publisher"}, {"key": "b11_92", "DOI": "10.1074/jbc.M313170200", "doi-asserted-by": "publisher"}, {"key": "b12_93", "DOI": "10.1074/jbc.274.21.14602", "doi-asserted-by": "publisher"}, {"key": "b13_94", "DOI": "10.1038/sj.embor.7400313", "doi-asserted-by": "publisher"}, {"key": "b14_95", "DOI": "10.1038/sj.onc.1208994", "doi-asserted-by": "publisher"}, {"key": "b15_96", "author": "Fleming ID", "year": "1997", "edition": "5", "volume-title": "AJCC Cancer Staging Manual"}, {"key": "b16_97", "author": "Gleason DF", "volume": "111", "first-page": "58", "year": "1974", "journal-title": "J Urol", "DOI": "10.1016/S0022-5347(17)59889-4", "doi-asserted-by": "crossref"}, {"key": "b17_98", "DOI": "10.1038/nm0798-844", "doi-asserted-by": "publisher"}, {"key": "b18_99", "author": "Harrell FE", "year": "2001", "volume-title": "Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis"}, {"key": "b19_100", "DOI": "10.1073/pnas.62.2.597", "doi-asserted-by": "publisher"}, {"key": "b20_101", "DOI": "10.1002/bies.950190309", "doi-asserted-by": "publisher"}, {"key": "b21_102", "DOI": "10.1016/S0092-8674(00)81846-2", "doi-asserted-by": "publisher"}, {"key": "b22_103", "DOI": "10.1074/jbc.274.30.21387", "doi-asserted-by": "publisher"}, {"key": "b23_104", "DOI": "10.1016/S0968-0004(03)00138-5", "doi-asserted-by": "publisher"}, {"key": "b24_105", "DOI": "10.1073/pnas.96.4.1303", "doi-asserted-by": "publisher"}, {"key": "b25_106", "DOI": "10.1093/nar/24.11.2036", "doi-asserted-by": "publisher"}, {"key": "b26_107", "DOI": "10.1073/pnas.93.21.11597", "doi-asserted-by": "publisher"}, {"key": "b27_108", "DOI": "10.1038/sj.onc.1201072", "doi-asserted-by": "publisher"}, {"key": "b28_109", "DOI": "10.1074/jbc.M303448200", "doi-asserted-by": "publisher"}, {"key": "b29_110", "DOI": "10.1074/jbc.272.39.24522", "doi-asserted-by": "publisher"}, {"key": "b30_111", "author": "Habraken Y", "volume": "269", "first-page": "31342", "year": "1994", "journal-title": "J Biol Chem"}, {"key": "b31_112", "DOI": "10.1016/S0167-4889(00)00029-X", "doi-asserted-by": "publisher"}, {"key": "b32_113", "DOI": "10.1073/pnas.152321699", "doi-asserted-by": "publisher"}, {"key": "b33_114", "DOI": "10.1074/jbc.272.8.4647", "doi-asserted-by": "publisher"}, {"key": "b34_115", "DOI": "10.1146/annurev.biochem.67.1.721", "doi-asserted-by": "publisher"}, {"key": "b35_116", "DOI": "10.1034/j.1399-0004.2001.590210.x", "doi-asserted-by": "publisher"}, {"key": "b36_117", "DOI": "10.1002/(SICI)1096-9896(1998110)186:3<319::AID-PATH184>3.0.CO;2-2", "doi-asserted-by": "publisher"}, {"key": "b37_118", "DOI": "10.1093/nar/26.8.2001", "doi-asserted-by": "publisher"}, {"key": "b38_119", "DOI": "10.1016/S1535-6108(03)00086-2", "doi-asserted-by": "publisher"}, {"key": "b39_120", "DOI": "10.1016/0888-7543(95)80129-A", "doi-asserted-by": "publisher"}, {"key": "b40_121", "DOI": "10.1038/sj.onc.1206977", "doi-asserted-by": "publisher"}, {"key": "b41_122", "DOI": "10.1016/S0022-5347(05)00034-0", "doi-asserted-by": "publisher"}, {"key": "b42_123", "DOI": "10.1056/NEJMoa040720", "doi-asserted-by": "publisher"}, {"key": "b43_124", "DOI": "10.1056/NEJMoa041318", "doi-asserted-by": "publisher"}, {"key": "b44_125", "DOI": "10.1002/1097-0142(20000915)89:6<1329::AID-CNCR19>3.0.CO;2-Q", "doi-asserted-by": "publisher"}, {"key": "b45_126", "DOI": "10.1016/j.bmcl.2004.07.028", "doi-asserted-by": "publisher"}, {"key": "b46_127", "DOI": "10.1016/j.bmcl.2004.10.086", "doi-asserted-by": "publisher"}], "container-title": ["BJU International"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-410X.2006.06224.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T10:51:23Z", "timestamp": 1547203883000}, "score": 49.148346, "issued": {"date-parts": [[2006, 8]]}, "references-count": 46, "journal-issue": {"published-print": {"date-parts": [[2006, 8]]}, "issue": "2"}, "alternative-id": ["10.1111/j.1464-410X.2006.06224.x"], "URL": "http://dx.doi.org/10.1111/j.1464-410x.2006.06224.x", "relation": {"cites": []}, "ISSN": ["1464-4096", "1464-410X"], "issn-type": [{"value": "1464-4096", "type": "print"}, {"value": "1464-410X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T05:10:17Z", "timestamp": 1575177017292}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2005, 4, 1]]}, "DOI": "10.1158/1078-0432.ccr-04-1842", "type": "journal-article", "created": {"date-parts": [[2005, 9, 21]], "date-time": "2005-09-21T23:46:06Z", "timestamp": 1127346366000}, "page": "2591-2596", "source": "Crossref", "is-referenced-by-count": 140, "title": ["Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases"], "prefix": "10.1158", "volume": "11", "author": [{"given": "J. S.", "family": "Lam", "sequence": "first", "affiliation": []}], "member": "1086", "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-04-1842", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T05:02:24Z", "timestamp": 1482469344000}, "score": 32.65455, "issued": {"date-parts": [[2005, 4, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 4, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-04-1842", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:39:45Z", "timestamp": 1574113185522}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2000, 12, 1]], "date-time": "2000-12-01T00:00:00Z", "timestamp": 975628800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer Prostatic Dis"], "published-print": {"date-parts": [[2000, 12]]}, "DOI": "10.1038/sj.pcan.4500470", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T20:03:52Z", "timestamp": 1031169832000}, "page": "229-235", "source": "Crossref", "is-referenced-by-count": 19, "title": ["In vitro human cell culture models for the study of prostate cancer"], "prefix": "10.1038", "volume": "3", "author": [{"given": "JS", "family": "Rhim", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2001, 1, 12]]}, "container-title": ["Prostate Cancer and Prostatic Diseases"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/4500470.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500470", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500470.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 15]], "date-time": "2019-04-15T15:26:04Z", "timestamp": 1555341964000}, "score": 28.816128, "issued": {"date-parts": [[2000, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2000, 12]]}, "issue": "4"}, "alternative-id": ["BF4500470"], "URL": "http://dx.doi.org/10.1038/sj.pcan.4500470", "ISSN": ["1365-7852", "1476-5608"], "issn-type": [{"value": "1365-7852", "type": "print"}, {"value": "1476-5608", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:39:06Z", "timestamp": 1574113146068}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1998, 12, 1]], "date-time": "1998-12-01T00:00:00Z", "timestamp": 912470400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer Prostatic Dis"], "published-print": {"date-parts": [[1998, 12]]}, "DOI": "10.1038/sj.pcan.4500257", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T20:07:11Z", "timestamp": 1031170031000}, "page": "297-300", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Does a family history of prostate cancer result in more aggressive disease?"], "prefix": "10.1038", "volume": "1", "author": [{"given": "EA", "family": "Klein", "sequence": "first", "affiliation": []}, {"given": "PA", "family": "Kupelian", "sequence": "additional", "affiliation": []}, {"given": "JS", "family": "Witte", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[1999, 1, 14]]}, "container-title": ["Prostate Cancer and Prostatic Diseases"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/4500257.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500257", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500257.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 15]], "date-time": "2019-04-15T15:24:23Z", "timestamp": 1555341863000}, "score": 25.601715, "issued": {"date-parts": [[1998, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1998, 12]]}, "issue": "6"}, "alternative-id": ["BF4500257"], "URL": "http://dx.doi.org/10.1038/sj.pcan.4500257", "ISSN": ["1365-7852", "1476-5608"], "issn-type": [{"value": "1365-7852", "type": "print"}, {"value": "1476-5608", "type": "electronic"}]}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T02:48:39Z", "timestamp": 1574822919221}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004, 2, 1]]}, "DOI": "10.21236/ada424506", "type": "report", "created": {"date-parts": [[2017, 8, 14]], "date-time": "2017-08-14T15:06:09Z", "timestamp": 1502723169000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Optimization and Characterization of Prostate Cancer Targeting Peptides"], "prefix": "10.21236", "author": [{"given": "Jan", "family": "Marik", "sequence": "first", "affiliation": []}, {"given": "Kit", "family": "Lam", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 8, 14]], "date-time": "2017-08-14T15:06:10Z", "timestamp": 1502723170000}, "score": 22.3431, "subtitle": [""], "issued": {"date-parts": [[2004, 2, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada424506"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:34:26Z", "timestamp": 1574282066288}, "reference-count": 0, "publisher": "Medknow", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Indian J Urol"], "published-print": {"date-parts": [[2007]]}, "DOI": "10.4103/0970-1591.30265", "type": "journal-article", "created": {"date-parts": [[2009, 2, 24]], "date-time": "2009-02-24T07:03:17Z", "timestamp": 1235458997000}, "page": "35", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Pathogenesis of prostate cancer and hormone refractory prostate cancer"], "prefix": "10.4103", "volume": "23", "author": [{"given": "DE", "family": "Neal", "sequence": "first", "affiliation": []}, {"given": "JS", "family": "Girling", "sequence": "additional", "affiliation": []}, {"given": "HC", "family": "Whitaker", "sequence": "additional", "affiliation": []}, {"given": "IG", "family": "Mills", "sequence": "additional", "affiliation": []}], "member": "2581", "container-title": ["Indian Journal of Urology"], "language": "en", "deposited": {"date-parts": [[2009, 2, 24]], "date-time": "2009-02-24T07:03:33Z", "timestamp": 1235459013000}, "score": 21.969128, "issued": {"date-parts": [[2007]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007]]}, "issue": "1"}, "alternative-id": ["30265"], "URL": "http://dx.doi.org/10.4103/0970-1591.30265", "ISSN": ["0970-1591"], "issn-type": [{"value": "0970-1591", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:58:48Z", "timestamp": 1574539128907}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 12, 15]]}, "DOI": "10.1158/0008-5472.sabcs13-p2-10-03", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:26:43Z", "timestamp": 1408055203000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P2-10-03: Metastasis-associated in colon cancer 1 predicts poor outcomes in patients with breast cancer"], "prefix": "10.1158", "author": [{"given": "JS", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "JS", "family": "Cho", "sequence": "additional", "affiliation": []}, {"given": "MH", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "JH", "family": "Yoon", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 3, 26]]}, "event": {"name": "Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS13-P2-10-03", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T19:56:05Z", "timestamp": 1558209365000}, "score": 21.729305, "issued": {"date-parts": [[2013, 12, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS13-P2-10-03"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs13-p2-10-03"}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T08:32:44Z", "timestamp": 1575448364270}, "reference-count": 0, "publisher": "Spandidos Publications", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Int J Oncol"], "DOI": "10.3892/ijo.5.6.1233", "type": "journal-article", "created": {"date-parts": [[2014, 3, 10]], "date-time": "2014-03-10T07:21:12Z", "timestamp": 1394436072000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["CURRENT STATUS OF PROSTATE-CANCER RESEARCH - DEVELOPMENT OF IN-VITRO MODEL SYSTEMS (REVIEW)"], "prefix": "10.3892", "author": [{"given": "JA", "family": "CHAH", "sequence": "first", "affiliation": []}, {"given": "JS", "family": "RHIM", "sequence": "additional", "affiliation": []}], "member": "2249", "published-online": {"date-parts": [[1994, 12, 1]]}, "container-title": ["International Journal of Oncology"], "link": [{"URL": "https://spandidos-publications.com/10.3892/ijo.5.6.1233/download", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 4, 27]], "date-time": "2017-04-27T09:55:45Z", "timestamp": 1493286945000}, "score": 21.378864, "issued": {"date-parts": [[1994, 12, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.3892/ijo.5.6.1233", "ISSN": ["1019-6439", "1791-2423"], "issn-type": [{"value": "1019-6439", "type": "print"}, {"value": "1791-2423", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T12:49:28Z", "timestamp": 1575204568927}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "2 Supplement", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Research"], "published-print": {"date-parts": [[2012, 1, 8]]}, "DOI": "10.1158/1538-7445.nonrna12-b21", "type": "journal-article", "created": {"date-parts": [[2013, 4, 3]], "date-time": "2013-04-03T15:13:51Z", "timestamp": 1365002031000}, "page": "B21-B21", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract B21: The paralogous microRNA clusters, miR-17-92 and miR-106-25, are specifically overexpressed in metastatic non-small cell lung carcinomas"], "prefix": "10.1158", "volume": "72", "author": [{"given": "K. S.", "family": "Enfield", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Lam", "sequence": "additional", "affiliation": []}, {"given": "W. L.", "family": "Lam", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2013, 4, 3]]}, "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.NONRNA12-B21", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T09:46:52Z", "timestamp": 1482486412000}, "score": 20.89095, "issued": {"date-parts": [[2012, 1, 8]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 4, 3]]}, "published-print": {"date-parts": [[2012, 1, 8]]}, "issue": "2 Supplement"}, "URL": "http://dx.doi.org/10.1158/1538-7445.nonrna12-b21", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"institution": {"name": "U.S. Army Medical Research Material Command", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T22:25:13Z", "timestamp": 1574807113514}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014, 10, 1]]}, "DOI": "10.21236/ada613420", "type": "report", "created": {"date-parts": [[2017, 7, 7]], "date-time": "2017-07-07T18:09:55Z", "timestamp": 1499450995000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Digital One-Disc-One-Compound Method for High-Throughput Discovery of Prostate Cancer-Targeting Ligands"], "prefix": "10.21236", "author": [{"given": "Tingrui", "family": "Pan", "sequence": "first", "affiliation": []}, {"given": "Kit", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "Gaomai", "family": "Yang", "sequence": "first", "affiliation": []}, {"given": "Zhongliang", "family": "Li", "sequence": "first", "affiliation": []}, {"given": "Wenwu", "family": "Xiao", "sequence": "first", "affiliation": []}, {"given": "Siwei", "family": "Zhao", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 7, 7]], "date-time": "2017-07-07T18:09:55Z", "timestamp": 1499450995000}, "score": 20.44678, "subtitle": [""], "issued": {"date-parts": [[2014, 10, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada613420"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:26:06Z", "timestamp": 1575303966690}, "publisher-location": "New York, NY", "reference-count": 75, "publisher": "Springer New York", "isbn-type": [{"value": "9781493978434", "type": "print"}, {"value": "9781493978458", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 1, 1]], "date-time": "2018-01-01T00:00:00Z", "timestamp": 1514764800000}, "delay-in-days": 0, "content-version": "unspecified"}, {"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 1, 1]], "date-time": "2018-01-01T00:00:00Z", "timestamp": 1514764800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018]]}, "DOI": "10.1007/978-1-4939-7845-8_1", "type": "book-chapter", "created": {"date-parts": [[2018, 5, 21]], "date-time": "2018-05-21T15:02:37Z", "timestamp": 1526914957000}, "page": "1-27", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance"], "prefix": "10.1007", "author": [{"given": "Hung-Ming", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "Holly M.", "family": "Nguyen", "sequence": "additional", "affiliation": []}, {"given": "Eva", "family": "Corey", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 5, 22]]}, "reference": [{"key": "1_CR1", "doi-asserted-by": "publisher", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono De", "year": "2011", "unstructured": "De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005", "journal-title": "N Engl J Med"}, {"key": "1_CR2", "doi-asserted-by": "publisher", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "volume": "367", "author": "HI Scher", "year": "2012", "unstructured": "Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197", "journal-title": "N Engl J Med"}, {"key": "1_CR3", "doi-asserted-by": "publisher", "first-page": "1272", "DOI": "10.1158/0008-5472.CAN-13-2921-T", "volume": "74", "author": "D Lin", "year": "2014", "unstructured": "Lin D, Wyatt AW, Xue H et al (2014) High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 74:1272\u20131283", "journal-title": "Cancer Res"}, {"key": "1_CR4", "doi-asserted-by": "publisher", "first-page": "Ra47", "DOI": "10.1126/scisignal.2005070", "volume": "7", "author": "L Li", "year": "2014", "unstructured": "Li L, Chang W, Yang G et al (2014) Targeting poly (Adp-ribose) polymerase and the C-Myb-regulated dna damage response pathway in castration-resistant prostate cancer. Sci Signal 7:Ra47", "journal-title": "Sci Signal"}, {"key": "1_CR5", "doi-asserted-by": "publisher", "first-page": "802", "DOI": "10.1016/j.ejca.2004.01.009", "volume": "40", "author": "HH Fiebig", "year": "2004", "unstructured": "Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802\u2013820", "journal-title": "Eur J Cancer"}, {"key": "1_CR6", "doi-asserted-by": "publisher", "first-page": "229", "DOI": "10.2353/ajpath.2010.090821", "volume": "177", "author": "H Zhao", "year": "2010", "unstructured": "Zhao H, Nolley R, Chen Z, Peehl DM (2010) Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 177:229\u2013239", "journal-title": "Am J Pathol"}, {"key": "1_CR7", "doi-asserted-by": "publisher", "first-page": "1901", "DOI": "10.2353/ajpath.2010.090873", "volume": "176", "author": "C Priolo", "year": "2010", "unstructured": "Priolo C, Agostini M, Vena N et al (2010) Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol 176:1901\u20131913", "journal-title": "Am J Pathol"}, {"key": "1_CR8", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1186/1479-5876-9-185", "volume": "9", "author": "O Raheem", "year": "2011", "unstructured": "Raheem O, Kulidjian AA, Wu C et al (2011) A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 9:185", "journal-title": "J Transl Med"}, {"key": "1_CR9", "doi-asserted-by": "publisher", "first-page": "2697", "DOI": "10.1172/JCI33637C1", "volume": "118", "author": "ZG Li", "year": "2008", "unstructured": "Li ZG, Mathew P, Yang J et\u00a0al (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through Fgf9-Mediated mechanisms. J Clin Invest 118:2697\u20132710", "journal-title": "J Clin Invest"}, {"key": "1_CR10", "doi-asserted-by": "publisher", "first-page": "1638", "DOI": "10.1002/pros.22517", "volume": "72", "author": "M Karlou", "year": "2012", "unstructured": "Karlou M, Lu JF, Wu G et al (2012) Hedgehog signaling inhibition by the small molecule smoothened inhibitor Gdc-0449 in the bone forming prostate cancer xenograft Mda Pca 118b. Prostate 72:1638\u20131647", "journal-title": "Prostate"}, {"key": "1_CR11", "doi-asserted-by": "publisher", "first-page": "846", "DOI": "10.1002/pros.21301", "volume": "71", "author": "A Aparicio", "year": "2011", "unstructured": "Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN (2011) Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient\u2019s tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71:846\u2013856", "journal-title": "Prostate"}, {"key": "1_CR12", "doi-asserted-by": "publisher", "first-page": "666", "DOI": "10.1158/1078-0432.CCR-11-1867", "volume": "18", "author": "V Tzelepi", "year": "2012", "unstructured": "Tzelepi V, Zhang J, Lu JF et al (2012) Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18:666\u2013677", "journal-title": "Clin Cancer Res"}, {"key": "1_CR13", "doi-asserted-by": "publisher", "first-page": "895", "DOI": "10.1016/j.ajpath.2011.11.030", "volume": "180", "author": "K Sircar", "year": "2012", "unstructured": "Sircar K, Huang H, Hu L et al (2012) Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180:895\u2013903", "journal-title": "Am J Pathol"}, {"key": "1_CR14", "doi-asserted-by": "publisher", "first-page": "1392", "DOI": "10.1038/labinvest.3700335", "volume": "85", "author": "Y Wang", "year": "2005", "unstructured": "Wang Y, Xue H, Cutz JC et al (2005) An orthotopic metastatic prostate cancer model in scid mice via grafting of a transplantable human prostate tumor line. Lab Investig 85:1392\u20131404", "journal-title": "Lab Investig"}, {"key": "1_CR15", "doi-asserted-by": "publisher", "first-page": "1636", "DOI": "10.1002/pros.21199", "volume": "70", "author": "D Lin", "year": "2010", "unstructured": "Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y (2010) Development of metastatic and non-metastatic tumor lines from a patient\u2019s prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate 70:1636\u20131644", "journal-title": "Prostate"}, {"key": "1_CR16", "doi-asserted-by": "publisher", "first-page": "628", "DOI": "10.1002/pros.22946", "volume": "75", "author": "PJ Russell", "year": "2015", "unstructured": "Russell PJ, Russell P, Rudduck C, Tse BW, Williams ED, Raghavan D (2015) Establishing prostate cancer patient derived xenografts: lessons learned from older studies. Prostate 75:628\u2013636", "journal-title": "Prostate"}, {"key": "1_CR17", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1002/pros.20255", "volume": "65", "author": "DR Mcculloch", "year": "2005", "unstructured": "Mcculloch DR, Opeskin K, Thompson EW, Williams ED (2005) Bm18: a novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis. Prostate 65:35\u201343", "journal-title": "Prostate"}, {"key": "1_CR18", "doi-asserted-by": "publisher", "first-page": "149", "DOI": "10.1002/pros.20225", "volume": "64", "author": "Y Wang", "year": "2005", "unstructured": "Wang Y, Revelo MP, Sudilovsky D et al (2005) Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64:149\u2013159", "journal-title": "Prostate"}, {"key": "1_CR19", "doi-asserted-by": "publisher", "first-page": "836", "DOI": "10.1038/nprot.2013.043", "volume": "8", "author": "MG Lawrence", "year": "2013", "unstructured": "Lawrence MG, Taylor RA, Toivanen R et al (2013) A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc 8:836\u2013848", "journal-title": "Nat Protoc"}, {"key": "1_CR20", "first-page": "1055", "volume": "149", "author": "WM Weerden Van", "year": "1996", "unstructured": "Van Weerden WM, De Ridder CM, Verdaasdonk CL, Romijn JC, Van Der Kwast TH, Schroder FH, Van Steenbrugge GJ (1996) Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 149:1055\u20131062", "journal-title": "Am J Pathol"}, {"key": "1_CR21", "doi-asserted-by": "publisher", "first-page": "286", "DOI": "10.1002/1097-0045(20000601)43:4<286::AID-PROS8>3.0.CO;2-0", "volume": "43", "author": "DG Bostwick", "year": "2000", "unstructured": "Bostwick DG, Ramnani D, Qian J (2000) Prostatic intraepithelial neoplasia: animal models 2000. Prostate 43:286\u2013294", "journal-title": "Prostate"}, {"key": "1_CR22", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1016/j.eururo.2005.12.035", "volume": "49", "author": "RB Marques", "year": "2006", "unstructured": "Marques RB, Van Weerden WM, Erkens-Schulze S, De Ridder CM, Bangma CH, Trapman J, Jenster G (2006) The human Pc346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol 49:245\u2013257", "journal-title": "Eur Urol"}, {"key": "1_CR23", "doi-asserted-by": "publisher", "first-page": "2846", "DOI": "10.1158/1078-0432.CCR-13-3309", "volume": "20", "author": "H Beltran", "year": "2014", "unstructured": "Beltran H, Tomlins S, Aparicio A et al (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20:2846\u20132850", "journal-title": "Clin Cancer Res"}, {"key": "1_CR24", "doi-asserted-by": "publisher", "first-page": "543", "DOI": "10.1016/S0002-9440(10)65300-X", "volume": "154", "author": "J Jongsma", "year": "1999", "unstructured": "Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, Van Der Kwast TH, Schroder FH, Van Steenbrugge GJ (1999) Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 154:543\u2013551", "journal-title": "Am J Pathol"}, {"key": "1_CR25", "first-page": "741", "volume": "60", "author": "J Jongsma", "year": "2000", "unstructured": "Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, Van Der Kwast TH, Schroder FH, Van Steenbrugge GJ (2000) Androgen deprivation of the Pc-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60:741\u2013748", "journal-title": "Cancer Res"}, {"key": "1_CR26", "doi-asserted-by": "publisher", "first-page": "705", "DOI": "10.1016/S0002-9440(10)64226-5", "volume": "161", "author": "LD True", "year": "2002", "unstructured": "True LD, Buhler K, Quinn J et\u00a0al (2002) A neuroendocrine/small cell prostate carcinoma xenograft-Lucap 49. Am J Pathol 161:705\u2013715", "journal-title": "Am J Pathol"}, {"key": "1_CR27", "author": "MFW Festing", "year": "1968", "unstructured": "Festing MFW (1968) International index of laboratory animals. University Of Leicester, Leicester", "volume-title": "International index of laboratory animals"}, {"key": "1_CR28", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.1159/000282323", "volume": "48", "author": "U Otto", "year": "1992", "unstructured": "Otto U, Wagner B, Becker H, Schroder S, Klosterhalfen H (1992) Transplantation of human benign hyperplastic prostate tissue into nude mice: first results of systemic therapy. Urol Int 48:167\u2013170", "journal-title": "Urol Int"}, {"key": "1_CR29", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1038/301527a0", "volume": "301", "author": "GC Bosma", "year": "1983", "unstructured": "Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301:527\u2013530", "journal-title": "Nature"}, {"key": "1_CR30", "first-page": "3798", "volume": "134", "author": "K Dorshkind", "year": "1985", "unstructured": "Dorshkind K, Pollack SB, Bosma MJ, Phillips RA (1985) Natural killer (Nk) cells are present in mice with severe combined immunodeficiency (Scid). J Immunol 134:3798\u20133801", "journal-title": "J Immunol"}, {"key": "1_CR31", "first-page": "2276", "volume": "134", "author": "AA Czitrom", "year": "1985", "unstructured": "Czitrom AA, Edwards S, Phillips RA, Bosma MJ, Marrack P, Kappler JW (1985) The function of antigen-presenting cells in mice with severe combined immunodeficiency. J Immunol 134:2276\u20132280", "journal-title": "J Immunol"}, {"key": "1_CR32", "first-page": "1804", "volume": "132", "author": "K Dorshkind", "year": "1984", "unstructured": "Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O\u2019toole M, Bosma MJ (1984) Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 132:1804\u20131808", "journal-title": "J Immunol"}, {"key": "1_CR33", "doi-asserted-by": "publisher", "first-page": "1016", "DOI": "10.1084/jem.167.3.1016", "volume": "167", "author": "GC Bosma", "year": "1988", "unstructured": "Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ (1988) Evidence of functional lymphocytes in some (Leaky) Scid mice. J Exp Med 167:1016\u20131033", "journal-title": "J Exp Med"}, {"key": "1_CR34", "first-page": "1087", "volume": "143", "author": "AM Carroll", "year": "1989", "unstructured": "Carroll AM, Hardy RR, Bosma MJ (1989) Occurrence of mature B (Igm+, B220+) And T (Cd3+) lymphocytes in Scid mice. J Immunol 143:1087\u20131093", "journal-title": "J Immunol"}, {"key": "1_CR35", "doi-asserted-by": "publisher", "first-page": "855", "DOI": "10.1016/0092-8674(92)90029-C", "volume": "68", "author": "Y Shinkai", "year": "1992", "unstructured": "Shinkai Y, Rathbun G, Lam KP et al (1992) Rag-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855\u2013867", "journal-title": "Cell"}, {"key": "1_CR36", "author": "A Kwant-Mitchell", "volume": "4", "year": "2009", "unstructured": "Kwant-Mitchell A, Pek EA, Rosenthal KL, Ashkar AA (2009) Development of functional human Nk cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS One 4:E8379", "journal-title": "PLoS One", "DOI": "10.1371/journal.pone.0008379", "doi-asserted-by": "publisher"}, {"key": "1_CR37", "doi-asserted-by": "publisher", "first-page": "191", "DOI": "10.1084/jem.177.1.191", "volume": "177", "author": "DE Mosier", "year": "1993", "unstructured": "Mosier DE, Stell KL, Gulizia RJ, Torbett BE, Gilmore GL (1993) Homozygous Scid/Scid;Beige/Beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med 177:191\u2013194", "journal-title": "J Exp Med"}, {"key": "1_CR38", "first-page": "180", "volume": "154", "author": "LD Shultz", "year": "1995", "unstructured": "Shultz LD, Schweitzer PA, Christianson SW et al (1995) Multiple defects in innate and adaptive immunologic function in Nod/Ltsz-Scid mice. J Immunol 154:180\u2013191", "journal-title": "J Immunol"}, {"key": "1_CR39", "doi-asserted-by": "publisher", "first-page": "295", "DOI": "10.1007/978-1-61779-243-4_17", "volume": "776", "author": "HM Nguyen", "year": "2011", "unstructured": "Nguyen HM, Corey E (2011) Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. Methods Mol Biol 776:295\u2013312", "journal-title": "Methods Mol Biol"}, {"key": "1_CR40", "doi-asserted-by": "publisher", "first-page": "407", "DOI": "10.4103/1008-682X.125394", "volume": "16", "author": "D Lin", "year": "2014", "unstructured": "Lin D, Xue H, Wang Y et al (2014) Next generation patient-derived prostate cancer xenograft models. Asian J Androl 16:407\u2013412", "journal-title": "Asian J Androl"}, {"key": "1_CR41", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1002/pros.22916", "volume": "75", "author": "VA Dipippo", "year": "2015", "unstructured": "Dipippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E (2015) Efficacy studies of an antibody-drug conjugate Psma-Adc in patient-derived prostate cancer xenografts. Prostate 75:303\u2013313", "journal-title": "Prostate"}, {"key": "1_CR42", "author": "HM Nguyen", "volume": "8", "year": "2013", "unstructured": "Nguyen HM, Ruppender N, Zhang X et al (2013) Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 8:E78881", "journal-title": "PLoS One", "DOI": "10.1371/journal.pone.0078881", "doi-asserted-by": "publisher"}, {"key": "1_CR43", "first-page": "1799", "volume": "70", "author": "C Morrissey", "year": "2010", "unstructured": "Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL (2010) Inhibition of angiopoietin-2 in Lucap 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 70:1799\u20131808", "journal-title": "Prostate"}, {"key": "1_CR44", "doi-asserted-by": "publisher", "first-page": "244", "DOI": "10.1186/1471-2407-10-244", "volume": "10", "author": "B Montgomery", "year": "2010", "unstructured": "Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E (2010) Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 10:244", "journal-title": "BMC Cancer"}, {"key": "1_CR45", "doi-asserted-by": "publisher", "first-page": "862", "DOI": "10.1593/neo.06328", "volume": "8", "author": "IM Coleman", "year": "2006", "unstructured": "Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey E (2006) Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8:862\u2013878", "journal-title": "Neoplasia"}, {"key": "1_CR46", "doi-asserted-by": "publisher", "first-page": "222", "DOI": "10.1002/ijc.21292", "volume": "118", "author": "A Stangelberger", "year": "2006", "unstructured": "Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R (2006) Targeted chemotherapy with cytotoxic bombesin analogue An-215 inhibits growth of experimental human prostate cancers. Int J Cancer 118:222\u2013229", "journal-title": "Int J Cancer"}, {"key": "1_CR47", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1002/pros.10198", "volume": "55", "author": "E Corey", "year": "2003", "unstructured": "Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL (2003) Lucap 35: a new model of prostate cancer progression to androgen independence. Prostate 55:239\u2013246", "journal-title": "Prostate"}, {"key": "1_CR48", "first-page": "1003", "volume": "8", "author": "E Corey", "year": "2002", "unstructured": "Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL (2002) Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 8:1003\u20131007", "journal-title": "Clin Cancer Res"}, {"key": "1_CR49", "first-page": "1038", "volume": "6", "author": "MA Rubin", "year": "2000", "unstructured": "Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ (2000) Rapid (\u201cWarm\u201d) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6:1038\u20131045", "journal-title": "Clin Cancer Res"}, {"key": "1_CR50", "doi-asserted-by": "publisher", "first-page": "578", "DOI": "10.1053/hp.2000.6698", "volume": "31", "author": "L Bubendorf", "year": "2000", "unstructured": "Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578\u2013583", "journal-title": "Hum Pathol"}, {"key": "1_CR51", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1007/978-1-4615-3398-6_18", "volume": "324", "author": "M Harada", "year": "1992", "unstructured": "Harada M, Iida M, Yamaguchi M, Shida K (1992) Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol 324:173\u2013182", "journal-title": "Adv Exp Med Biol"}, {"key": "1_CR52", "doi-asserted-by": "publisher", "first-page": "3078", "DOI": "10.1002/1097-0142(19841215)54:12<3078::AID-CNCR2820541245>3.0.CO;2-U", "volume": "54", "author": "H Saitoh", "year": "1984", "unstructured": "Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T (1984) Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54:3078\u20133084", "journal-title": "Cancer"}, {"key": "1_CR53", "doi-asserted-by": "publisher", "first-page": "646", "DOI": "10.1016/S0046-8177(03)00190-4", "volume": "34", "author": "MP Roudier", "year": "2003", "unstructured": "Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34:646\u2013653", "journal-title": "Hum Pathol"}, {"key": "1_CR54", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1007/978-1-4419-9129-4_13", "volume": "118", "author": "MP Roudier", "year": "2004", "unstructured": "Roudier MP, Corey E, True LD, Hiagno CS, Ott SM, Vessell RL (2004) Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 118:311\u2013339", "journal-title": "Cancer Treat Res"}, {"key": "1_CR55", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1002/pros.10091", "volume": "52", "author": "E Corey", "year": "2002", "unstructured": "Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Rl V (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52:20\u201333", "journal-title": "Prostate"}, {"key": "1_CR56", "first-page": "295", "volume": "9", "author": "E Corey", "year": "2003", "unstructured": "Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295\u2013306", "journal-title": "Clin Cancer Res"}, {"key": "1_CR57", "doi-asserted-by": "publisher", "first-page": "15", "DOI": "10.1186/1471-2407-6-15", "volume": "6", "author": "KD Brubaker", "year": "2006", "unstructured": "Brubaker KD, Brown LG, Vessella RL, Corey E (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15", "journal-title": "BMC Cancer"}, {"key": "1_CR58", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1038/sj.bjc.6605178", "volume": "101", "author": "T Koreckij", "year": "2009", "unstructured": "Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101:263\u2013268", "journal-title": "Br J Cancer"}, {"key": "1_CR59", "doi-asserted-by": "publisher", "first-page": "861", "DOI": "10.1002/pros.20752", "volume": "68", "author": "TM Morgan", "year": "2008", "unstructured": "Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E (2008) Rad001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68:861\u2013871", "journal-title": "Prostate"}, {"key": "1_CR60", "doi-asserted-by": "publisher", "first-page": "50", "DOI": "10.1002/pros.20494", "volume": "67", "author": "V Kundra", "year": "2007", "unstructured": "Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM (2007) In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 67:50\u201360", "journal-title": "Prostate"}, {"key": "1_CR61", "doi-asserted-by": "publisher", "first-page": "3646", "DOI": "10.1158/0008-5472.CAN-06-1210", "volume": "67", "author": "Y Lu", "year": "2007", "unstructured": "Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J (2007) Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67:3646\u20133653", "journal-title": "Cancer Res"}, {"key": "1_CR62", "doi-asserted-by": "publisher", "first-page": "1235", "DOI": "10.1172/JCI11685", "volume": "107", "author": "J Zhang", "year": "2001", "unstructured": "Zhang J, Dai J, Qi Y et al (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235\u20131244", "journal-title": "J Clin Invest"}, {"key": "1_CR63", "first-page": "600", "volume": "50", "author": "PV Turner", "year": "2011", "unstructured": "Turner PV, Brabb T, Pekow C, Vasbinder MA (2011) Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50:600\u2013613", "journal-title": "J Am Assoc Lab Anim Sci"}, {"key": "1_CR64", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1177/039139880502800204", "volume": "28", "author": "L Gotloib", "year": "2005", "unstructured": "Gotloib L, Wajsbrot V, Shostak A (2005) A short review of experimental peritoneal sclerosis: from mice to men. Int J Artif Organs 28:97\u2013104", "journal-title": "Int J Artif Organs"}, {"key": "1_CR65", "first-page": "562", "volume": "178", "author": "G Lukas", "year": "1971", "unstructured": "Lukas G, Brindle SD, Greengard P (1971) The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 178:562\u2013564", "journal-title": "J Pharmacol Exp Ther"}, {"key": "1_CR66", "doi-asserted-by": "publisher", "first-page": "377", "DOI": "10.1007/s10585-007-9116-4", "volume": "25", "author": "C Morrissey", "year": "2008", "unstructured": "Morrissey C, True LD, Roudier MP et al (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 25:377\u2013388", "journal-title": "Clin Exp Metastasis"}, {"key": "1_CR67", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1002/jbmr.1749", "volume": "28", "author": "C Morrissey", "year": "2013", "unstructured": "Morrissey C, Roudier MP, Dowell AT et al (2013) Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University Of Washington Rapid Autopsy Series. J Bone Miner Res 28:333\u2013340", "journal-title": "J Bone Miner Res"}, {"key": "1_CR68", "first-page": "302", "volume": "52", "author": "B Ristevski", "year": "2009", "unstructured": "Ristevski B, Jenkinson RJ, Stephen DJ, Finkelstein J, Schemitsch EH, Mckee MD, Kreder HJ (2009) Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg 52:302\u2013308", "journal-title": "Can J Surg"}, {"key": "1_CR69", "doi-asserted-by": "publisher", "first-page": "1316", "DOI": "10.1002/pros.22677", "volume": "73", "author": "JP Michiel Sedelaar", "year": "2013", "unstructured": "Michiel Sedelaar JP, Dalrymple SS, Isaacs JT (2013) Of mice and men\u2014warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 73:1316\u20131325", "journal-title": "Prostate"}, {"key": "1_CR70", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1210/mend.12.1.0050", "volume": "12", "author": "M Janne", "year": "1998", "unstructured": "Janne M, Deol HK, Power SG, Yee SP, Hammond GL (1998) Human sex hormone-binding globulin gene expression in transgenic mice. Mol Endocrinol 12:123\u2013136", "journal-title": "Mol Endocrinol"}, {"key": "1_CR71", "doi-asserted-by": "publisher", "first-page": "857", "DOI": "10.1016/0024-3205(92)90204-3", "volume": "50", "author": "WM Weerden Van", "year": "1992", "unstructured": "Van Weerden WM, Bierings HG, Van Steenbrugge GJ, De Jong FH, Schroder FH (1992) Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 50:857\u2013861", "journal-title": "Life Sci"}, {"key": "1_CR72", "doi-asserted-by": "publisher", "first-page": "5913", "DOI": "10.1158/1078-0432.CCR-11-0728", "volume": "17", "author": "EA Mostaghel", "year": "2011", "unstructured": "Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance To Cyp17a1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913\u20135925", "journal-title": "Clin Cancer Res"}, {"key": "1_CR73", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1186/1423-0127-18-63", "volume": "18", "author": "CP Chuu", "year": "2011", "unstructured": "Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC (2011) Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 18:63", "journal-title": "J Biomed Sci"}, {"key": "1_CR74", "doi-asserted-by": "publisher", "first-page": "2194", "DOI": "10.1002/ijc.26159", "volume": "129", "author": "AK Wege", "year": "2011", "unstructured": "Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel DN, Ortmann O, Kroemer A, Brockhoff G (2011) Humanized tumor mice\u2014a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer 129:2194\u20132206", "journal-title": "Int J Cancer"}, {"key": "1_CR75", "doi-asserted-by": "publisher", "first-page": "629", "DOI": "10.1002/pros.20726", "volume": "68", "author": "KJ Pienta", "year": "2008", "unstructured": "Pienta KJ, Abate-Shen C, Agus DB et al (2008) The current state of preclinical prostate cancer animal models. Prostate 68:629\u2013639", "journal-title": "Prostate"}], "container-title": ["Methods in Molecular Biology", "Prostate Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-1-4939-7845-8_1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 6, 29]], "date-time": "2018-06-29T02:07:35Z", "timestamp": 1530238055000}, "score": 19.935812, "issued": {"date-parts": [[2018]]}, "ISBN": ["9781493978434", "9781493978458"], "references-count": 75, "URL": "http://dx.doi.org/10.1007/978-1-4939-7845-8_1", "relation": {"cites": []}, "ISSN": ["1064-3745", "1940-6029"], "issn-type": [{"value": "1064-3745", "type": "print"}, {"value": "1940-6029", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T06:05:48Z", "timestamp": 1574575548797}, "publisher-location": "London", "reference-count": 55, "publisher": "Springer London", "isbn-type": [{"value": "9780857294814", "type": "print"}, {"value": "9780857294821", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2015]]}, "DOI": "10.1007/978-0-85729-482-1_47", "type": "book-chapter", "created": {"date-parts": [[2015, 1, 16]], "date-time": "2015-01-16T19:26:41Z", "timestamp": 1421436401000}, "page": "807-816", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Management of Locally Advanced Prostate Cancer"], "prefix": "10.1007", "author": [{"given": "Elaine T.", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "L. Michael", "family": "Glod\u00e9", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 11, 4]]}, "reference": [{"issue": "1", "key": "47_CR1", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.3322/caac.21208", "volume": "64", "author": "R Siegel", "year": "2014", "unstructured": "Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9\u201329.", "journal-title": "CA Cancer J Clin"}, {"key": "47_CR2", "unstructured": "Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79(2):235\u201346.", "DOI": "10.1046/j.1464-410X.1997.d01-6840.x", "doi-asserted-by": "crossref"}, {"issue": "9", "key": "47_CR3", "doi-asserted-by": "publisher", "first-page": "1309", "DOI": "10.1111/j.1464-410X.2011.10760.x", "volume": "109", "author": "WT Lowrance", "year": "2012", "unstructured": "Lowrance WT, Elkin EB, Yees DS, et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int. 2012;109(9):1309\u201314.", "journal-title": "BJU Int"}, {"issue": "2", "key": "47_CR4", "doi-asserted-by": "crossref", "first-page": "162", "DOI": "10.6004/jnccn.2010.0012", "volume": "8", "author": "J Mohler", "year": "2010", "unstructured": "Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162\u2013200.", "journal-title": "J Natl Compr Canc Netw"}, {"issue": "12", "key": "47_CR5", "doi-asserted-by": "publisher", "first-page": "1868", "DOI": "10.1200/JCO.2005.04.7423", "volume": "24", "author": "UE Studer", "year": "2006", "unstructured": "Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868\u201376.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "47_CR6", "doi-asserted-by": "publisher", "first-page": "923", "DOI": "10.1097/01.ju.0000135742.13171.d2", "volume": "172", "author": "FH Schroder", "year": "2004", "unstructured": "Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol. 2004;172(3):923\u20137.", "journal-title": "J Urol"}, {"issue": "1", "key": "47_CR7", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1016/j.eururo.2008.09.008", "volume": "55", "author": "FH Schroder", "year": "2009", "unstructured": "Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009;55(1):14\u201322.", "journal-title": "Eur Urol"}, {"issue": "6", "key": "47_CR8", "doi-asserted-by": "publisher", "first-page": "472", "DOI": "10.1016/S1470-2045(06)70700-8", "volume": "7", "author": "EM Messing", "year": "2006", "unstructured": "Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472\u20139.", "journal-title": "Lancet Oncol"}, {"issue": "9660", "key": "47_CR9", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.1016/S0140-6736(08)61815-2", "volume": "373", "author": "A Widmark", "year": "2009", "unstructured": "Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301\u20138.", "journal-title": "Lancet"}, {"issue": "9809", "key": "47_CR10", "doi-asserted-by": "publisher", "first-page": "2104", "DOI": "10.1016/S0140-6736(11)61095-7", "volume": "378", "author": "P Warde", "year": "2011", "unstructured": "Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104\u201311.", "journal-title": "Lancet"}, {"issue": "5", "key": "47_CR11", "doi-asserted-by": "publisher", "first-page": "1243", "DOI": "10.1016/S0360-3016(01)01579-6", "volume": "50", "author": "MV Pilepich", "year": "2001", "unstructured": "Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243\u201352.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"issue": "4", "key": "47_CR12", "doi-asserted-by": "publisher", "first-page": "585", "DOI": "10.1200/JCO.2007.13.9881", "volume": "26", "author": "M Roach 3rd", "year": "2008", "unstructured": "Roach 3rd M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585\u201391.", "journal-title": "J Clin Oncol"}, {"issue": "21", "key": "47_CR13", "doi-asserted-by": "publisher", "first-page": "3972", "DOI": "10.1200/JCO.2003.11.023", "volume": "21", "author": "GE Hanks", "year": "2003", "unstructured": "Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21(21):3972\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "15", "key": "47_CR14", "doi-asserted-by": "publisher", "first-page": "2497", "DOI": "10.1200/JCO.2007.14.9021", "volume": "26", "author": "EM Horwitz", "year": "2008", "unstructured": "Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497\u2013504.", "journal-title": "J Clin Oncol"}, {"issue": "9327", "key": "47_CR15", "doi-asserted-by": "publisher", "first-page": "103", "DOI": "10.1016/S0140-6736(02)09408-4", "volume": "360", "author": "M Bolla", "year": "2002", "unstructured": "Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103\u20136.", "journal-title": "Lancet"}, {"issue": "3", "key": "47_CR16", "doi-asserted-by": "crossref", "first-page": "289", "DOI": "10.1001/jama.299.3.289", "volume": "299", "author": "AV D\u2019Amico", "year": "2008", "unstructured": "D\u2019Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289\u201395.", "journal-title": "JAMA"}, {"issue": "16", "key": "47_CR17", "doi-asserted-by": "publisher", "first-page": "2829", "DOI": "10.1517/14656566.9.16.2829", "volume": "9", "author": "TW Flaig", "year": "2008", "unstructured": "Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008;9(16):2829\u201341.", "journal-title": "Expert Opin Pharmacother"}, {"issue": "4", "key": "47_CR18", "first-page": "465", "volume": "166", "author": "VB Shahinian", "year": "2006", "unstructured": "Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465\u201371.", "journal-title": "Arch Intern Med"}, {"issue": "6 Pt 1", "key": "47_CR19", "doi-asserted-by": "publisher", "first-page": "2443", "DOI": "10.1016/j.juro.2006.07.151", "volume": "176", "author": "F Joly", "year": "2006", "unstructured": "Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6 Pt 1):2443\u20137.", "journal-title": "J Urol"}, {"issue": "5", "key": "47_CR20", "doi-asserted-by": "publisher", "first-page": "1182", "DOI": "10.1016/j.urology.2010.03.033", "volume": "76", "author": "TM Beer", "year": "2010", "unstructured": "Beer TM, Benavides M, Emmons SL, et al. Acupuncture for hot flashes in patients with prostate cancer. Urology. 2010;76(5):1182\u20138.", "journal-title": "Urology"}, {"issue": "9", "key": "47_CR21", "doi-asserted-by": "publisher", "first-page": "735", "DOI": "10.1111/j.1442-2042.2004.00896.x", "volume": "11", "author": "T Nishiyama", "year": "2004", "unstructured": "Nishiyama T, Kanazawa S, Watanbe R, Jacobsen PB. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004;11(9):735\u201341.", "journal-title": "Int J Urol"}, {"issue": "6", "key": "47_CR22", "doi-asserted-by": "publisher", "first-page": "598", "DOI": "10.1002/pon.1427", "volume": "18", "author": "EW Ulloa", "year": "2009", "unstructured": "Ulloa EW, Salup R, Patterson SG, et al. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer. Psychooncology. 2009;18(6):598\u2013605.", "journal-title": "Psychooncology"}, {"issue": "6", "key": "47_CR23", "doi-asserted-by": "publisher", "first-page": "635", "DOI": "10.1016/S0210-4806(09)74201-9", "volume": "33", "author": "SV Gonzalez", "year": "2009", "unstructured": "Gonzalez SV, Puig FM, Marti SS, et al. [Trazodone: a new selective approach to the treatment of hot flashes induced by androgen deprivation in prostate carcinoma?]. Actas Urol Esp. 2009;33(6):635\u20138.", "journal-title": "Actas Urol Esp"}, {"issue": "12", "key": "47_CR24", "doi-asserted-by": "publisher", "first-page": "6410", "DOI": "10.1210/jc.2005-0183", "volume": "90", "author": "SL Greenspan", "year": "2005", "unstructured": "Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410\u20137.", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "3", "key": "47_CR25", "doi-asserted-by": "publisher", "first-page": "500", "DOI": "10.1016/j.urology.2006.11.002", "volume": "69", "author": "J Morote", "year": "2007", "unstructured": "Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500\u20134.", "journal-title": "Urology"}, {"issue": "9768", "key": "47_CR26", "doi-asserted-by": "publisher", "first-page": "813", "DOI": "10.1016/S0140-6736(10)62344-6", "volume": "377", "author": "K Fizazi", "year": "2011", "unstructured": "Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322.", "journal-title": "Lancet"}, {"issue": "9810", "key": "47_CR27", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.1016/S0140-6736(11)61226-9", "volume": "379", "author": "MR Smith", "year": "2012", "unstructured": "Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39\u201346.", "journal-title": "Lancet"}, {"issue": "2", "key": "47_CR28", "doi-asserted-by": "publisher", "first-page": "520", "DOI": "10.1016/j.juro.2006.03.057", "volume": "176", "author": "J Yannucci", "year": "2006", "unstructured": "Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176(2):520\u20135.", "journal-title": "J Urol"}, {"issue": "24", "key": "47_CR29", "doi-asserted-by": "publisher", "first-page": "3979", "DOI": "10.1200/JCO.2006.05.9741", "volume": "24", "author": "M Braga-Basaria", "year": "2006", "unstructured": "Braga-Basaria M, Dobbs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979\u201383.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "47_CR30", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.3322/caac.20061", "volume": "60", "author": "GN Levine", "year": "2010", "unstructured": "Levine GN, D\u2019Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194\u2013201.", "journal-title": "CA Cancer J Clin"}, {"issue": "5", "key": "47_CR31", "doi-asserted-by": "publisher", "first-page": "451", "DOI": "10.1016/S1470-2045(11)70063-8", "volume": "12", "author": "JW Denham", "year": "2011", "unstructured": "Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451\u20139.", "journal-title": "Lancet Oncol"}, {"issue": "2", "key": "47_CR32", "doi-asserted-by": "publisher", "first-page": "189", "DOI": "10.1016/S1470-2045(11)70295-9", "volume": "13", "author": "AV D\u2019Amico", "year": "2012", "unstructured": "D\u2019Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012;13(2):189\u201395.", "journal-title": "Lancet Oncol"}, {"issue": "6", "key": "47_CR33", "first-page": "456", "volume": "61", "author": "F Rodriguez-Covarrubias", "year": "2009", "unstructured": "Rodriguez-Covarrubias F, Castillejos-Molina RA, Sotomayor M, et al. The role of radical prostatectomy in the management of patients with high-grade prostate cancer and/or locally advanced disease. Rev Invest Clin. 2009;61(6):456\u201360.", "journal-title": "Rev Invest Clin"}, {"issue": "9", "key": "47_CR34", "doi-asserted-by": "publisher", "first-page": "1508", "DOI": "10.1200/JCO.2009.22.2265", "volume": "28", "author": "MJ Zelefsky", "year": "2010", "unstructured": "Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508\u201313.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "47_CR35", "doi-asserted-by": "publisher", "first-page": "1357", "DOI": "10.1016/S0022-5347(01)66266-9", "volume": "155", "author": "BL Dalkin", "year": "1996", "unstructured": "Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996;155(4):1357\u201360.", "journal-title": "J Urol"}, {"issue": "1", "key": "47_CR36", "doi-asserted-by": "publisher", "first-page": "28", "DOI": "10.1080/003655902317259337", "volume": "36", "author": "G Aus", "year": "2002", "unstructured": "Aus G, Adolfsson J, Selli C, Widmark A. Treatment of patients with clinical T3 prostate cancer. Scand J Urol Nephrol. 2002;36(1):28\u201333.", "journal-title": "Scand J Urol Nephrol"}, {"issue": "3", "key": "47_CR37", "doi-asserted-by": "publisher", "first-page": "479", "DOI": "10.1016/S0090-4295(97)00020-4", "volume": "50", "author": "F Labrie", "year": "1997", "unstructured": "Labrie F. Flutamide plus castration in patients with previously untreated prostate cancer. Urology. 1997;50(3):479.", "journal-title": "Urology"}, {"issue": "Suppl 1", "key": "47_CR38", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1159/000052302", "volume": "35", "author": "D Prezioso", "year": "1999", "unstructured": "Prezioso D, Lotti T, Montironi R, Polito M. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group. Eur Urol. 1999;35 Suppl 1:17\u201321; discussion 22.", "journal-title": "Eur Urol"}, {"issue": "6", "key": "47_CR39", "doi-asserted-by": "publisher", "first-page": "706", "DOI": "10.1159/000020366", "volume": "38", "author": "CC Schulman", "year": "2000", "unstructured": "Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706\u201313.", "journal-title": "Eur Urol"}, {"issue": "1", "key": "47_CR40", "doi-asserted-by": "publisher", "first-page": "112", "DOI": "10.1016/S0022-5347(05)65393-1", "volume": "167", "author": "MS Soloway", "year": "2002", "unstructured": "Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112\u20136.", "journal-title": "J Urol"}, {"issue": "7", "key": "47_CR41", "doi-asserted-by": "publisher", "first-page": "508", "DOI": "10.1136/jcp.55.7.508", "volume": "55", "author": "C Selli", "year": "2002", "unstructured": "Selli C, Montironi R, Bono A, et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. 2002;55(7):508\u201313.", "journal-title": "J Clin Pathol"}, {"key": "47_CR42", "unstructured": "Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4):CD006019.", "DOI": "10.1002/14651858.CD006019.pub2", "doi-asserted-by": "crossref"}, {"issue": "1", "key": "47_CR43", "doi-asserted-by": "publisher", "first-page": "19", "DOI": "10.4111/kju.2011.52.1.19", "volume": "52", "author": "SW Yang", "year": "2011", "unstructured": "Yang SW, Song KH, Lim JS, Sul CK. Neoadjuvant hormonal therapy preceding radical prostatectomy for clinically localized prostate cancer: early postoperative complications and biochemical recurrence. Korean J Urol. 2011;52(1):19\u201323.", "journal-title": "Korean J Urol"}, {"issue": "2", "key": "47_CR44", "doi-asserted-by": "crossref", "first-page": "228", "DOI": "10.6004/jnccn.2010.0015", "volume": "8", "author": "ME Nielsen", "year": "2010", "unstructured": "Nielsen ME, Trock BJ, Walsh PC. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw. 2010;8(2):228\u201337.", "journal-title": "J Natl Compr Canc Netw"}, {"issue": "15", "key": "47_CR45", "doi-asserted-by": "publisher", "first-page": "2040", "DOI": "10.1200/JCO.2010.32.2776", "volume": "29", "author": "TB Dorff", "year": "2011", "unstructured": "Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011;29(15):2040\u20135.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "47_CR46", "doi-asserted-by": "publisher", "first-page": "267", "DOI": "10.1016/j.eururo.2003.10.013", "volume": "45", "author": "MP Wirth", "year": "2004", "unstructured": "Wirth MP, Weissbach L, Marx FJ, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol. 2004;45(3):267\u201370; discussion 270.", "journal-title": "Eur Urol"}, {"issue": "Suppl 5", "key": "47_CR47", "first-page": "S29", "volume": "7", "author": "DG McLeod", "year": "2005", "unstructured": "McLeod DG. The effective management of biochemical recurrence in patients with prostate cancer. Rev Urol. 2005;7 Suppl 5:S29\u201336.", "journal-title": "Rev Urol"}, {"issue": "3", "key": "47_CR48", "doi-asserted-by": "publisher", "first-page": "672", "DOI": "10.1016/j.ijrobp.2008.05.020", "volume": "73", "author": "SA Rosenthal", "year": "2009", "unstructured": "Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009;73(3):672\u20138.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"issue": "3", "key": "47_CR49", "doi-asserted-by": "publisher", "first-page": "212", "DOI": "10.3816/CGC.2005.n.035", "volume": "4", "author": "AR Patel", "year": "2005", "unstructured": "Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer. 2005;4(3):212\u20134.", "journal-title": "Clin Genitourin Cancer"}, {"issue": "10", "key": "47_CR50", "doi-asserted-by": "publisher", "first-page": "1909", "DOI": "10.1200/JCO.2004.02.001", "volume": "22", "author": "P Kumar", "year": "2004", "unstructured": "Kumar P, Perotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22(10):1909\u201315.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "47_CR51", "doi-asserted-by": "publisher", "first-page": "276", "DOI": "10.1016/j.urolonc.2007.04.003", "volume": "26", "author": "M Perrotti", "year": "2008", "unstructured": "Perrotti M, Doyle T, Kumar P, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol. 2008;26(3):276\u201380.", "journal-title": "Urol Oncol"}, {"issue": "18", "key": "47_CR52", "doi-asserted-by": "publisher", "first-page": "2973", "DOI": "10.1200/JCO.2007.14.4105", "volume": "26", "author": "NJ Sanfilippo", "year": "2008", "unstructured": "Sanfilippo NJ, et al. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol. 2008;26(18):2973\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "47_CR53", "doi-asserted-by": "publisher", "first-page": "774", "DOI": "10.1016/S0090-4295(02)02519-0", "volume": "61", "author": "M Hussain", "year": "2003", "unstructured": "Hussain M, Smith DC, El-Rays BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774\u201380.", "journal-title": "Urology"}, {"issue": "1", "key": "47_CR54", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1007/s11255-009-9580-7", "volume": "42", "author": "D Hirano", "year": "2010", "unstructured": "Hirano D, Nagane Y, Satoh K, et al. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. Int Urol Nephrol. 2010;42(1):81\u20138.", "journal-title": "Int Urol Nephrol"}, {"key": "47_CR55", "author": "A Marciscano", "year": "2012", "unstructured": "Marciscano A, Hardee M, Sanfilippo NJ. Management of high-risk localized prostate cancer. Adv Urol. 2012. doi:\n                10.1155/2012/641689\n                \n              .", "journal-title": "Adv Urol", "DOI": "10.1155/2012/641689", "doi-asserted-by": "publisher"}], "container-title": ["Urological Oncology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-0-85729-482-1_47", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 29]], "date-time": "2019-05-29T04:14:36Z", "timestamp": 1559103276000}, "score": 19.857548, "issued": {"date-parts": [[2014, 11, 4]]}, "ISBN": ["9780857294814", "9780857294821"], "references-count": 55, "URL": "http://dx.doi.org/10.1007/978-0-85729-482-1_47", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T13:20:32Z", "timestamp": 1575206432644}, "reference-count": 166, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 6, 1]], "date-time": "2013-06-01T00:00:00Z", "timestamp": 1370044800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oral Oncology"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1016/j.oraloncology.2013.03.001", "type": "journal-article", "created": {"date-parts": [[2013, 4, 6]], "date-time": "2013-04-06T10:45:23Z", "timestamp": 1365245123000}, "page": "507-524", "source": "Crossref", "is-referenced-by-count": 47, "title": ["Speech and swallowing following tongue cancer surgery and free flap reconstruction \u2013 A systematic review"], "prefix": "10.1016", "volume": "49", "author": [{"given": "Lisetta", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "Nabil", "family": "Samman", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Oral Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1368837513000614?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1368837513000614?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 17]], "date-time": "2018-10-17T04:00:23Z", "timestamp": 1539748823000}, "score": 19.84532, "issued": {"date-parts": [[2013, 6]]}, "references-count": 166, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "6"}, "alternative-id": ["S1368837513000614"], "URL": "http://dx.doi.org/10.1016/j.oraloncology.2013.03.001", "ISSN": ["1368-8375"], "issn-type": [{"value": "1368-8375", "type": "print"}], "subject": ["Cancer Research", "Oral Surgery", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:02:58Z", "timestamp": 1574488978412}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1990, 5, 1]], "date-time": "1990-05-01T00:00:00Z", "timestamp": 641520000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[1990, 5]]}, "DOI": "10.1038/bjc.1990.146", "type": "journal-article", "created": {"date-parts": [[2011, 1, 14]], "date-time": "2011-01-14T10:44:56Z", "timestamp": 1295001896000}, "page": "649-651", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Has chemotherapy proved itself in head and neck cancer?"], "prefix": "10.1038", "volume": "61", "author": [{"given": "JS", "family": "Tobias", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bjc1990146.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1990146", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1990146.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 18]], "date-time": "2019-03-18T17:02:18Z", "timestamp": 1552928538000}, "score": 19.756788, "issued": {"date-parts": [[1990, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1990, 5]]}, "issue": "5"}, "alternative-id": ["BFbjc1990146"], "URL": "http://dx.doi.org/10.1038/bjc.1990.146", "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:31:18Z", "timestamp": 1575304278088}, "reference-count": 45, "publisher": "Frontiers Media SA", "license": [{"URL": "https://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2018, 5, 22]], "date-time": "2018-05-22T00:00:00Z", "timestamp": 1526947200000}, "delay-in-days": 0, "content-version": "unspecified"}], "funder": [{"DOI": "10.13039/100000002", "name": "National Institutes of Health", "doi-asserted-by": "publisher", "award": ["R21 CA194798, P50 CA097186, P01 CA163227, P30 CA015704"]}], "content-domain": {"domain": ["frontiersin.org"], "crossmark-restriction": true}, "short-container-title": ["Front. Oncol."], "DOI": "10.3389/fonc.2018.00167", "type": "journal-article", "created": {"date-parts": [[2018, 5, 22]], "date-time": "2018-05-22T08:25:06Z", "timestamp": 1526977506000}, "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer"], "prefix": "10.3389", "volume": "8", "author": [{"given": "Hung-Ming", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "Eva", "family": "Corey", "sequence": "additional", "affiliation": []}], "member": "1965", "published-online": {"date-parts": [[2018, 5, 22]]}, "reference": [{"key": "B1", "doi-asserted-by": "publisher", "first-page": "997", "DOI": "10.1016/S0022-5347(17)71004-X", "article-title": "Studies on prostatic cancer III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prosate", "volume": "46", "author": "Huggins", "year": "1941", "journal-title": "J Urol"}, {"key": "B2", "doi-asserted-by": "publisher", "first-page": "1665", "DOI": "10.1158/1078-0432.CCR-06-0067", "article-title": "Mechanisms underlying the development of androgen-independent prostate cancer", "volume": "12", "author": "Pienta", "year": "2006", "journal-title": "Clin Cancer Res"}, {"key": "B3", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1056/NEJMoa1209096", "article-title": "Abiraterone in metastatic prostate cancer without previous chemotherapy", "volume": "368", "author": "Ryan", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "B4", "doi-asserted-by": "publisher", "first-page": "610", "DOI": "10.1038/ncpuro1237", "article-title": "CYP17 inhibition as a hormonal strategy for prostate cancer", "volume": "5", "author": "Reid", "year": "2008", "journal-title": "Nat Clin Pract Urol"}, {"key": "B5", "doi-asserted-by": "publisher", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "article-title": "Increased survival with enzalutamide in prostate cancer after chemotherapy", "volume": "367", "author": "Scher", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "B6", "doi-asserted-by": "publisher", "first-page": "884", "DOI": "10.1016/j.ctrv.2015.08.002", "article-title": "Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer", "volume": "41", "author": "Buttigliero", "year": "2015", "journal-title": "Cancer Treat Rev"}, {"key": "B7", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1007/s11934-016-0584-4", "article-title": "Novel insights into molecular indicators of response and resistance to modern androgen-axis therapies in prostate cancer", "volume": "17", "author": "Silberstein", "year": "2016", "journal-title": "Curr Urol Rep"}, {"key": "B8", "first-page": "1163", "article-title": "Two principles in endocrine therapy of cancers: hormone deprival and hormone interference", "volume": "25", "author": "Huggins", "year": "1965", "journal-title": "Cancer Res"}, {"key": "B9", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1016/j.mce.2004.04.013", "article-title": "Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells", "volume": "222", "author": "Attardi", "year": "2004", "journal-title": "Mol Cell Endocrinol"}, {"key": "B10", "doi-asserted-by": "publisher", "first-page": "15152", "DOI": "10.1073/pnas.93.26.15152", "article-title": "Androgen-repressed phenotype in human prostate cancer", "volume": "93", "author": "Zhau", "year": "1996", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "B11", "first-page": "1566", "article-title": "Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation", "volume": "54", "author": "Kokontis", "year": "1994", "journal-title": "Cancer Res"}, {"key": "B12", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1210/mend.12.7.0136", "article-title": "Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest", "volume": "12", "author": "Kokontis", "year": "1998", "journal-title": "Mol Endocrinol"}, {"key": "B13", "doi-asserted-by": "publisher", "first-page": "e109170", "DOI": "10.1371/journal.pone.0109170", "article-title": "Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2", "volume": "9", "author": "Kokontis", "year": "2014", "journal-title": "PLoS One"}, {"key": "B14", "first-page": "5622", "article-title": "Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline", "volume": "63", "author": "Hara", "year": "2003", "journal-title": "Cancer Res"}, {"key": "B15", "first-page": "3474", "article-title": "Negative controls of cell proliferation: human prostate cancer cells and androgens", "volume": "49", "author": "Sonnenschein", "year": "1989", "journal-title": "Cancer Res"}, {"key": "B16", "doi-asserted-by": "publisher", "first-page": "10185", "DOI": "10.1073/pnas.97.18.10185", "article-title": "Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator", "volume": "97", "author": "Geck", "year": "2000", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "B17", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1016/S0960-0760(97)00122-2", "article-title": "Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells", "volume": "63", "author": "Geck", "year": "1997", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "B18", "doi-asserted-by": "publisher", "first-page": "2708", "DOI": "10.1210/endo.143.7.8899", "article-title": "Mechanism of androgen action on cell proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate", "volume": "143", "author": "Maffini", "year": "2002", "journal-title": "Endocrinology"}, {"key": "B19", "doi-asserted-by": "publisher", "first-page": "2082", "DOI": "10.1158/0008-5472.CAN-04-3992", "article-title": "Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice", "volume": "65", "author": "Chuu", "year": "2005", "journal-title": "Cancer Res"}, {"key": "B20", "doi-asserted-by": "publisher", "first-page": "2022", "DOI": "10.1111/j.1349-7006.2011.02043.x", "article-title": "Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc", "volume": "102", "author": "Chuu", "year": "2011", "journal-title": "Cancer Sci"}, {"key": "B21", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1186/1423-0127-18-63", "article-title": "Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer", "volume": "18", "author": "Chuu", "year": "2011", "journal-title": "J Biomed Sci"}, {"key": "B22", "doi-asserted-by": "publisher", "first-page": "E166", "DOI": "10.3390/cancers9120166", "article-title": "Supraphysiologic testosterone therapy in the treatment of prostate cancer: models, mechanisms and questions", "volume": "9", "author": "Mohammad", "year": "2017", "journal-title": "Cancers (Basel)"}, {"key": "B23", "doi-asserted-by": "publisher", "first-page": "1329", "DOI": "10.1002/pros.20483", "article-title": "PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor", "volume": "66", "author": "Litvinov", "year": "2006", "journal-title": "Prostate"}, {"key": "B24", "doi-asserted-by": "publisher", "first-page": "1618", "DOI": "10.1016/j.celrep.2014.11.008", "article-title": "Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity", "volume": "9", "author": "Cai", "year": "2014", "journal-title": "Cell Rep"}, {"key": "B25", "doi-asserted-by": "publisher", "first-page": "372", "DOI": "10.1016/S0022-5347(17)54531-0", "article-title": "The response of metastatic adenocarcinoma of the prostate to exogenous testosterone", "volume": "126", "author": "Fowler", "year": "1981", "journal-title": "J Urol"}, {"key": "B26", "doi-asserted-by": "publisher", "first-page": "1373", "DOI": "10.1002/1097-0142(19820401)49:7<1373::AID-CNCR2820490712>3.0.CO;2-G", "article-title": "Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer", "volume": "49", "author": "Fowler", "year": "1982", "journal-title": "Cancer"}, {"key": "B27", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1016/j.eururo.2009.03.073", "article-title": "Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer", "volume": "56", "author": "Morris", "year": "2009", "journal-title": "Eur Urol"}, {"key": "B28", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1016/j.eururo.2009.02.022", "article-title": "A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer", "volume": "56", "author": "Szmulewitz", "year": "2009", "journal-title": "Eur Urol"}, {"key": "B29", "doi-asserted-by": "publisher", "first-page": "1397", "DOI": "10.1111/j.1464-410X.2009.08980.x", "article-title": "Testosterone replacement in prostate cancer survivors with hypogonadal symptoms", "volume": "105", "author": "Leibowitz", "year": "2010", "journal-title": "BJU Int"}, {"key": "B30", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1093/annonc/mdm568", "article-title": "Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial", "volume": "19", "author": "Mathew", "year": "2008", "journal-title": "Ann Oncol"}, {"key": "B31", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1002/cncr.22438", "article-title": "Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy", "volume": "109", "author": "Sarosdy", "year": "2007", "journal-title": "Cancer"}, {"key": "B32", "doi-asserted-by": "publisher", "first-page": "269ra262", "DOI": "10.1126/scitranslmed.3010563", "article-title": "Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study", "volume": "7", "author": "Schweizer", "year": "2015", "journal-title": "Sci Transl Med"}, {"key": "B33", "doi-asserted-by": "publisher", "first-page": "1215", "DOI": "10.1016/j.cell.2015.05.001", "article-title": "Integrative clinical genomics of advanced prostate cancer", "volume": "161", "author": "Robinson", "year": "2015", "journal-title": "Cell"}, {"key": "B34", "doi-asserted-by": "publisher", "first-page": "1218", "DOI": "10.1002/pros.23209", "article-title": "Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study", "volume": "76", "author": "Schweizer", "year": "2016", "journal-title": "Prostate"}, {"key": "B35", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1016/S1470-2045(17)30906-3", "article-title": "Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study", "volume": "19", "author": "Teply", "year": "2017", "journal-title": "Lancet Oncol"}, {"key": "B36", "doi-asserted-by": "publisher", "first-page": "474", "DOI": "10.1016/j.ccell.2017.09.003", "article-title": "Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling", "volume": "32", "author": "Bluemn", "year": "2017", "journal-title": "Cancer Cell"}, {"key": "B37", "doi-asserted-by": "publisher", "first-page": "3310", "DOI": "10.1158/1078-0432.CCR-15-1147", "article-title": "Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation", "volume": "22", "author": "Hedayati", "year": "2016", "journal-title": "Clin Cancer Res"}, {"key": "B38", "doi-asserted-by": "publisher", "first-page": "1491", "DOI": "10.1002/pros.22504", "article-title": "Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer", "volume": "72", "author": "Isaacs", "year": "2012", "journal-title": "Prostate"}, {"key": "B39", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1634/theoncologist.6-2-177", "article-title": "Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients", "volume": "6", "author": "Leibowitz", "year": "2001", "journal-title": "Oncologist"}, {"key": "B40", "doi-asserted-by": "publisher", "first-page": "920", "DOI": "10.1097/01.ju.0000136269.10161.32", "article-title": "Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men", "volume": "172", "author": "Kaufman", "year": "2004", "journal-title": "J Urol"}, {"key": "B41", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.1097/01.ju.0000143942.55896.64", "article-title": "Testosterone replacement therapy after primary treatment for prostate cancer", "volume": "173", "author": "Agarwal", "year": "2005", "journal-title": "J Urol"}, {"key": "B42", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.1007/s11934-010-0143-3", "article-title": "Androgen replacement therapy after prostate cancer treatment", "volume": "11", "author": "Khera", "year": "2010", "journal-title": "Curr Urol Rep"}, {"key": "B43", "doi-asserted-by": "publisher", "first-page": "1261", "DOI": "10.1001/jamaoncol.2015.2895", "article-title": "Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis", "volume": "1", "author": "Magnan", "year": "2015", "journal-title": "JAMA Oncol"}, {"key": "B44", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1200/JCO.2015.64.1019", "article-title": "Intermittent androgen deprivation in prostate cancer: are we ready to quit?", "volume": "34", "author": "Park", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "B45", "doi-asserted-by": "publisher", "first-page": "1816", "DOI": "10.1038/s41467-017-01968-5", "article-title": "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer", "volume": "8", "author": "Zhang", "year": "2017", "journal-title": "Nat Commun"}], "container-title": ["Frontiers in Oncology"], "link": [{"URL": "https://www.frontiersin.org/article/10.3389/fonc.2018.00167/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 5, 22]], "date-time": "2018-05-22T08:25:11Z", "timestamp": 1526977511000}, "score": 19.455994, "issued": {"date-parts": [[2018, 5, 22]]}, "references-count": 45, "alternative-id": ["10.3389/fonc.2018.00167"], "URL": "http://dx.doi.org/10.3389/fonc.2018.00167", "relation": {"cites": []}, "ISSN": ["2234-943X"], "issn-type": [{"value": "2234-943X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T17:35:38Z", "timestamp": 1574184938921}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 3, 1]], "date-time": "2006-03-01T00:00:00Z", "timestamp": 1141171200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Urologic Oncology: Seminars and Original Investigations"], "published-print": {"date-parts": [[2006, 3]]}, "DOI": "10.1016/j.urolonc.2005.11.038", "type": "journal-article", "created": {"date-parts": [[2006, 3, 8]], "date-time": "2006-03-08T12:21:46Z", "timestamp": 1141820506000}, "page": "131-140", "source": "Crossref", "is-referenced-by-count": 17, "title": ["RETRACTED: Stem cells in prostate and prostate cancer development"], "prefix": "10.1016", "volume": "24", "author": [{"given": "John S.", "family": "Lam", "sequence": "first", "affiliation": []}, {"given": "Robert E.", "family": "Reiter", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Urologic Oncology: Seminars and Original Investigations"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1078143905002632?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1078143905002632?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 1]], "date-time": "2019-05-01T21:05:47Z", "timestamp": 1556744747000}, "score": 19.450504, "issued": {"date-parts": [[2006, 3]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 3]]}, "issue": "2"}, "alternative-id": ["S1078143905002632"], "URL": "http://dx.doi.org/10.1016/j.urolonc.2005.11.038", "ISSN": ["1078-1439"], "issn-type": [{"value": "1078-1439", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T21:08:27Z", "timestamp": 1574716107219}, "reference-count": 0, "publisher": "eLife Sciences Publications, Ltd", "license": [{"URL": "http://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2015, 5, 22]], "date-time": "2015-05-22T00:00:00Z", "timestamp": 1432252800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": []}, "published-print": {"date-parts": [[2015, 5, 22]]}, "DOI": "10.7554/elife.06434.003", "type": "peer-review", "created": {"date-parts": [[2015, 7, 31]], "date-time": "2015-07-31T09:13:36Z", "timestamp": 1438334016000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Author response: Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44"], "prefix": "10.7554", "author": [{"given": "Jia", "family": "Li", "sequence": "first", "affiliation": [{"name": "Crown Bioscience, Santa Clara, California, United States"}]}, {"given": "Matthew", "family": "Lam", "sequence": "additional", "affiliation": [{"name": "Breakthrough Breast Cancer, London, United Kingdom"}]}, {"name": "Reproducibility Project: Cancer Biology", "sequence": "additional", "affiliation": []}], "member": "4374", "review": {"type": "author-comment", "stage": "pre-publication"}, "deposited": {"date-parts": [[2019, 11, 12]], "date-time": "2019-11-12T00:26:19Z", "timestamp": 1573518379000}, "score": 19.06865, "issued": {"date-parts": [[2015, 5, 22]]}, "references-count": 0, "URL": "http://dx.doi.org/10.7554/elife.06434.003", "relation": {"is-review-of": [{"id-type": "doi", "id": "10.7554/eLife.06434", "asserted-by": "subject"}]}}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:11:08Z", "timestamp": 1574107868684}, "reference-count": 21, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2003, 12, 1]], "date-time": "2003-12-01T00:00:00Z", "timestamp": 1070236800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer Prostatic Dis"], "published-print": {"date-parts": [[2003, 12]]}, "DOI": "10.1038/sj.pcan.4500679", "type": "journal-article", "created": {"date-parts": [[2003, 12, 9]], "date-time": "2003-12-09T08:06:53Z", "timestamp": 1070957213000}, "page": "301-304", "source": "Crossref", "is-referenced-by-count": 58, "title": ["Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study"], "prefix": "10.1038", "volume": "6", "author": [{"given": "B W", "family": "Guess", "sequence": "first", "affiliation": []}, {"given": "M C", "family": "Scholz", "sequence": "additional", "affiliation": []}, {"given": "S B", "family": "Strum", "sequence": "additional", "affiliation": []}, {"given": "R Y", "family": "Lam", "sequence": "additional", "affiliation": []}, {"given": "H J", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "R I", "family": "Jennrich", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2003, 12, 9]]}, "reference": [{"key": "BF4500679_CR1", "first-page": "177", "volume": "2", "author": "I Eliaz", "year": "2002", "unstructured": "Eliaz I . The potential role of modified citrus pectin in the prevention of cancer metastasis. Clin Pract Altern Med 2002; 2: 177\u2013179.", "journal-title": "Clin Pract Altern Med"}, {"key": "BF4500679_CR2", "doi-asserted-by": "publisher", "first-page": "433", "DOI": "10.1007/BF00144274", "volume": "6", "author": "A Raz", "year": "1987", "unstructured": "Raz A, Lotan R . Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metast Rev 1987; 6: 433\u2013452.", "journal-title": "Cancer Metast Rev"}, {"key": "BF4500679_CR3", "doi-asserted-by": "publisher", "first-page": "776", "DOI": "10.1002/(SICI)1097-0142(19970815)80:4<776::AID-CNCR17>3.0.CO;2-Q", "volume": "80", "author": "RS Bresalier", "year": "1997", "unstructured": "Bresalier RS et al. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997; 80: 776\u2013787.", "journal-title": "Cancer"}, {"key": "BF4500679_CR4", "doi-asserted-by": "publisher", "first-page": "2979", "DOI": "10.1002/j.1460-2075.1984.tb02244.x", "volume": "3", "author": "A Raz", "year": "1984", "unstructured": "Raz A et al. Monoclonal antibodies to endogenous galactose-specific tumor cell lectins. EMBO J 1984; 3: 2979\u20132983.", "journal-title": "EMBO J"}, {"key": "BF4500679_CR5", "first-page": "4", "volume": "1", "author": "P Kidd", "year": "1996", "unstructured": "Kidd P . A new approach to metastatic cancer prevention: modified citrus pectin (MCP), a unique pectin that blocks cell surface lectins. Altern Med Rev 1996; 1: 4\u201310.", "journal-title": "Altern Med Rev"}, {"key": "BF4500679_CR6", "unstructured": "Naik H, Kalemkerian G . Inhibition of in vitro tumor cell-endothelial adhesion by modified citrus pectin: a pH modified natural complex carbohydrate [abstr]. Proceedings of the Annual Meeting of the American Association of Cancer Research A377, 1995."}, {"key": "BF4500679_CR7", "doi-asserted-by": "publisher", "first-page": "348", "DOI": "10.1093/jnci/87.5.348", "volume": "87", "author": "KJ Pienta", "year": "1995", "unstructured": "Pienta KJ et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348\u2013353.", "journal-title": "J Natl Cancer Inst"}, {"key": "BF4500679_CR8", "doi-asserted-by": "publisher", "first-page": "1854", "DOI": "10.1093/jnci/94.24.1854", "volume": "94", "author": "P Nangia-Makker", "year": "2002", "unstructured": "Nangia-Makker P, Conklin J, Hogan V, Raz A . Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854\u20131862.", "journal-title": "J Natl Cancer Inst"}, {"key": "BF4500679_CR9", "doi-asserted-by": "publisher", "first-page": "2031", "DOI": "10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q", "volume": "71", "author": "HP Schmid", "year": "1993", "unstructured": "Schmid HP, McNeal JE, Stamey TC . Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031.", "journal-title": "Cancer"}, {"key": "BF4500679_CR10", "doi-asserted-by": "publisher", "first-page": "909", "DOI": "10.1056/NEJM198710083171501", "volume": "317", "author": "TA Stamey", "year": "1987", "unstructured": "Stamey TA et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909\u2013916.", "journal-title": "N Engl J Med"}, {"key": "BF4500679_CR11", "doi-asserted-by": "publisher", "first-page": "1070", "DOI": "10.1016/S0022-5347(17)41174-8", "volume": "141", "author": "TA Stamey", "year": "1989", "unstructured": "Stamey TA, Kabalin JN . Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070\u20131075.", "journal-title": "J Urol"}, {"key": "BF4500679_CR12", "doi-asserted-by": "publisher", "first-page": "88", "DOI": "10.1002/pros.10176", "volume": "54", "author": "B Guess", "year": "2003", "unstructured": "Guess B et al. Using splines to detect changes in PSA doubling times. Prostate 2003; 54: 88\u201394.", "journal-title": "Prostate"}, {"key": "BF4500679_CR13", "doi-asserted-by": "publisher", "first-page": "1591", "DOI": "10.1001/jama.281.17.1591", "volume": "281", "author": "CR Pound", "year": "1999", "unstructured": "Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591\u20131597.", "journal-title": "JAMA"}, {"key": "BF4500679_CR14", "doi-asserted-by": "publisher", "first-page": "576", "DOI": "10.1016/S0025-6196(11)62406-3", "volume": "76", "author": "SG Roberts", "year": "2001", "unstructured": "Roberts SG et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 576\u2013581.", "journal-title": "Mayo Clin Proc"}, {"key": "BF4500679_CR15", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1016/S0360-3016(97)00082-5", "volume": "38", "author": "CI Sartor", "year": "1997", "unstructured": "Sartor CI et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997; 38: 941\u2013947.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "BF4500679_CR16", "doi-asserted-by": "publisher", "first-page": "230", "DOI": "10.1200/JCO.1997.15.1.230", "volume": "15", "author": "RW Lee", "year": "1997", "unstructured": "Lee RW, Hanks GE, Hanlan A . Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15: 230\u2013238.", "journal-title": "J Clin Oncol"}, {"key": "BF4500679_CR17", "doi-asserted-by": "publisher", "first-page": "670", "DOI": "10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO;2-8", "volume": "74", "author": "A Pollack", "year": "1994", "unstructured": "Pollack A, Zagars GK, Kavadi VS . Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994; 74: 670\u2013678.", "journal-title": "Cancer"}, {"key": "BF4500679_CR18", "doi-asserted-by": "publisher", "first-page": "342", "DOI": "10.1002/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z", "volume": "82", "author": "DB McLaren", "year": "1998", "unstructured": "McLaren DB, McKenzie M, Duncan G, Pickles T . Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early-untreated prostate carcinoma. Cancer 1998; 82: 342\u2013348.", "journal-title": "Cancer"}, {"key": "BF4500679_CR19", "doi-asserted-by": "publisher", "first-page": "2035", "DOI": "10.1016/S0022-5347(01)63236-1", "volume": "159", "author": "C Gross", "year": "1998", "unstructured": "Gross C, Stamey TS, Hancock S, Feldman D . Treatment of early recurrent prostate cancer with 1,25 dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035\u20132039.", "journal-title": "J Urol"}, {"key": "BF4500679_CR20", "doi-asserted-by": "publisher", "first-page": "1217", "DOI": "10.1002/cncr.11179", "volume": "97", "author": "TM Beer", "year": "2003", "unstructured": "Beer TM, Lemmon D, Lowe BA, Henner DW . High-dose weekly oral calcitriol in patients with a rising psa after prostatectomy or radiation for prostate carcinoma. Cancer. 2003; 97: 1217\u20131224.", "journal-title": "Cancer"}, {"key": "BF4500679_CR21", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1200/jco.2003.05.117", "volume": "21", "author": "TM Beer", "year": "2003", "unstructured": "Beer TM et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123\u2013128.", "journal-title": "J Clin Oncol"}], "container-title": ["Prostate Cancer and Prostatic Diseases"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/4500679.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500679", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500679.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 15]], "date-time": "2019-04-15T14:46:13Z", "timestamp": 1555339573000}, "score": 18.99146, "issued": {"date-parts": [[2003, 12]]}, "references-count": 21, "journal-issue": {"published-print": {"date-parts": [[2003, 12]]}, "issue": "4"}, "alternative-id": ["BF4500679"], "URL": "http://dx.doi.org/10.1038/sj.pcan.4500679", "relation": {"cites": []}, "ISSN": ["1365-7852", "1476-5608"], "issn-type": [{"value": "1365-7852", "type": "print"}, {"value": "1476-5608", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:03:08Z", "timestamp": 1574488988822}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1992, 6, 1]], "date-time": "1992-06-01T00:00:00Z", "timestamp": 707356800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[1992, 6]]}, "DOI": "10.1038/bjc.1992.202", "type": "journal-article", "created": {"date-parts": [[2011, 1, 14]], "date-time": "2011-01-14T11:02:32Z", "timestamp": 1295002952000}, "page": "967-967", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Surgery in metastatic non-seminomatous germ cell tumours"], "prefix": "10.1038", "volume": "65", "author": [{"given": "JS", "family": "Tobias", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bjc1992202.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1992202", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1992202.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T06:22:17Z", "timestamp": 1552717337000}, "score": 18.966263, "issued": {"date-parts": [[1992, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992, 6]]}, "issue": "6"}, "alternative-id": ["BFbjc1992202"], "URL": "http://dx.doi.org/10.1038/bjc.1992.202", "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:58:47Z", "timestamp": 1574539127348}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 12, 15]]}, "DOI": "10.1158/0008-5472.sabcs13-al-1", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:26:43Z", "timestamp": 1408055203000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract AL-1: AACR outstanding investigator award for breast cancer research: Understanding estrogen receptor transcription in breast cancer"], "prefix": "10.1158", "author": [{"given": "JS", "family": "Carroll", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 3, 26]]}, "event": {"name": "Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX"}, "container-title": ["Invited Speaker Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS13-AL-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T19:54:53Z", "timestamp": 1558209293000}, "score": 18.966263, "issued": {"date-parts": [[2013, 12, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS13-AL-1"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs13-al-1"}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}